| DESCRIPTION | - AKASHI, Curr. Opin. Genet. Dev., (20010000), vol. 11, no. 6, pages 660 - 666 | - |
| DESCRIPTION | - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 3402 | - |
| DESCRIPTION | - BAUER S et al., Proc Natl. Acad. Sci. USA, (20010000), vol. 98, pages 9237 - 9242 | - |
| DESCRIPTION | - BERGER et al., Clin Cancer Res., (20080000), vol. 14, no. 10, pages 3044 - 3051 | - |
| DESCRIPTION | - BOUR-JORDAN et al., Immunol Rev., (20110000), vol. 241, no. 1, pages 180 - 205 | - |
| DESCRIPTION | - BRAHMER et al., J Clin Oncol., (20100000), vol. 28, no. 19, pages 3167 - 3175 | - |
| DESCRIPTION | - BRAHMER et al., N Engl J Med., (20120000), vol. 366, no. 26, pages 2455 - 2465 | - |
| DESCRIPTION | - BRAHMER, J Clin Oncol., (20100000), vol. 28, no. 19, pages 3167 - 3175 | - |
| DESCRIPTION | - CURRAN, Proc Natl Acad Sci U S A, (20100000), vol. 107, no. 9, pages 4275 - 4280 | - |
| DESCRIPTION | - DAI et al., Mol Ther., (20120000), vol. 20, no. 9, pages 1800 - 1809 | - |
| DESCRIPTION | - DONG et al., Nat Med., (20020000), vol. 8, no. 8, pages 793 - 800 | - |
| DESCRIPTION | - ELBASHIR et al., Nature, (20010000), vol. 411, pages 494 - 498 | - |
| DESCRIPTION | - FOTIN-MLECZEK et al., J Gene Med., (20120000), vol. 14, no. 6, pages 428 - 439 | - |
| DESCRIPTION | - GenBank, Database accession no. U26404, URL: ncbi | - |
| DESCRIPTION | - GenBank, Database accession no. X65300, URL: ncbi | - |
| DESCRIPTION | - GenBank, Database accession no. X65327, URL: ncbi | - |
| DESCRIPTION | - HANNON, Nature, (20020000), vol. 41, pages 244 - 251 | - |
| DESCRIPTION | - HE; KATZE, Viral Immunol., (20020000), vol. 15, pages 95 - 119 | - |
| DESCRIPTION | - HEMMI H et al., Nature, (20000000), vol. 408, pages 740 - 745 | - |
| DESCRIPTION | - HOBO et al., Cancer Immunol Immunother., (20130000), vol. 62, no. 2, pages 285 - 297 | - |
| DESCRIPTION | - HOLCIK et al., Proc. Natl. Acad. Sci. USA, (19970000), vol. 94, pages 2410 - 2414 | - |
| DESCRIPTION | - KARLIN et al., PNAS, (19930000), vol. 90, pages 5873 - 5877 | - |
| DESCRIPTION | - KOHLER; MILSTEIN, Nature, (19750000), vol. 256, page 495 | - |
| DESCRIPTION | - KONTERMANN R.E., Acta Pharmacol. Sin, (20050000), vol. 26, no. 1, pages 1 - 9 | - |
| DESCRIPTION | - LAI et al., Development, (19950000), vol. 121, pages 2349 - 2360 | - |
| DESCRIPTION | - MCCAFFERTY, Nature, (19900000), vol. 348, pages 552 - 554 | - |
| DESCRIPTION | - MEYLAN, E.; TSCHOPP, J., "Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses", Mol. Cell, (20060000), vol. 22, pages 561 - 569 | - |
| DESCRIPTION | - MKRTICHYA et al., Eur J Immunol., (20110000), vol. 41, no. 10, pages 2977 - 2986 | - |
| DESCRIPTION | - MKRTICHYAN et al., J Immunol., (20120000), vol. 189, no. 5, pages 2338 - 2347 | - |
| DESCRIPTION | - NISHIMURA, Immunity, (19990000), vol. 11, no. 2, pages 141 - 151 | - |
| DESCRIPTION | - OKAZAKI; HONJO, Int Immunol., (20070000), vol. 19, no. 7, pages 813 - 824 | - |
| DESCRIPTION | - PERRI, J. Virol., (20030000), vol. 77, no. 19, pages 10394 - 10403 | - |
| DESCRIPTION | - PILON-THOMAS et al., J Immunol., (20100000), vol. 184, no. 7, pages 3442 - 3449 | - |
| DESCRIPTION | - SHARP, Genes Dev., (20010000), vol. 5, pages 485 - 490 | - |
| DESCRIPTION | - SIERRO, Eur J lmmunol., (20110000), vol. 41, no. 8, pages 2217 - 2228 | - |
| DESCRIPTION | - STARK et al., Annu. Rev. Biochem., (19980000), vol. 67, pages 227 - 264 | - |
| DESCRIPTION | - TOPALIAN et al., N Engl J Med., (20120000), vol. 366, no. 26, pages 2443 - 2454 | - |
| DESCRIPTION | - ZAMORE, Nat. Struct. Biol., (20010000), vol. 9, pages 746 - 750 | - |
| DESCRIPTION | - ZITVOGEL; KROEMER, Oncoimmunology, (20120000), vol. 1, pages 1223 - 1125 | - |
| DESCRIPTION | - VANDER VEEN et al., "Alphavirus replicon vaccines", Animal Health Research Reviews, (20120000), vol. 13, no. 1, doi:doi:10.1017/S1466252312000011, pages 1 - 9, XP009166113 | |
| OPPOSITION | - Agarwal and Vogelzang, "Development of novel immune interventions for genito-urinary cancers", Agarwal and Vogelzang, Agarwal and Vogelzang, Cancer vaccines: from research to clinical practice, (20110000), pages 25 - 43, XP055492086 | - |
| OPPOSITION | - AGARWAL, NEERAJ et al., "Development of novel immune interventions for genito-urinary cancers", Cancer Vaccines: From Research to Clinical Practice, (20111123), pages 25 - 43, XP055492086 | - |
| OPPOSITION | - BECK et al., "6th Annual European Antibody Congress 2010", mAbs, (20110000), vol. 3, pages 111 - 132, XP055680455 | - |
| OPPOSITION | - Clinical trial profile of the trial having, (20130100), URL: ClinicalTrials.gov | - |
| OPPOSITION | - Clinical trial profile of the trial having, URL: ClinicalTrials.gov | - |
| OPPOSITION | - FOTIN-MLECZEK et al., "Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity", Journal of Immunotherapy, (20110000), vol. 34, pages 1 - 15, XP002665988 | - |
| OPPOSITION | - Hoerr Ingmar, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", TISSUE ENGINEERING, LARCHMONT, NY, US, US, (20070401), vol. 13, no. 4, ISSN 1076-3279, pages 886 - 887, XP091251215 | - |
| OPPOSITION | - Hoerr, "OP57 - Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", Tissue Engineering, (20070000), vol. 13, no. 4, pages 886 - 887, XP091251215 | - |
| OPPOSITION | - HUNG, CHIEN-FU et al., "DNA vaccines for cervical 2007 cancer: from bench to bedside", Experimental & molecular medicine, (20070000), vol. 39.6, pages 679 - 689, XP055680726 | - |
| OPPOSITION | - LI et al., "Potent Systemic Antitumor Immunity 2007 Induced by Vaccination with Chemotactic- Prostate Tumor Associated Antigen Gene - Modified Tumor Cell and Blockade of B7-H1", J. Clin. Immunol., (20070000), vol. 27, pages 117 - 130, XP019481374 | - |
| OPPOSITION | - MACKENSEN, A., "Peptide and RNA-based 2011 vaccines for the treatment of cancer", Onkologie, (20110000), vol. 34, page 202, XP055493075 | - |
| OPPOSITION | - "nVivoMab anti-mouse PD-1 (CD279)", Product Sheet | - |
| OPPOSITION | - Paul J Converse, 605402, (20001114), OMIM, URL: https://omim.org/entry/605402?search=PDL1&highlight=pdl1, (20191223), XP055682181 | - |
| OPPOSITION | - ROSENBLATT, JACALYN et al., "CT-011, Anti-PD-1 2009 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma", Blood, (20090000), pages 781 - 781, XP008180498 | - |
| OPPOSITION | - SOARES, KEVIN C. et al., "Granulocyte 2012 macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer", Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances ; Dec 2-5, 2012 ; Miami, FL. Philadelphia (PA ) : AACR; Cancer Res 2013, vol. 73, no. 1, XP055493192 | - |
| OPPOSITION | - VOGELZANG, N.J. et al., "3 Development of novel immune interventions for genito-urinary cancers", Cancer Vaccines: From Research to Clinical Practice, (20110000), pages 25 - 43, XP055492086 | - |
| OPPOSITION | - MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", European Journal of Immunology, (19930000), vol. 23, doi:10.1002/eji.1830230749, pages 1719 - 1722, XP002937540 | |
| OPPOSITION | - MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.", European Journal of Immunology, (19930000), vol. 23, pages 1719 - 1722, XP000618955 | |
| OPPOSITION | - SIERRA, S. et al., "Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity", Eur. J. Immunol., (20110000), vol. 41, pages 2217 - 2228, XP002716011 | |
| OPPOSITION | - SIERRO et al., "Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity", Eur. J. Immunol., (20110000), vol. 41, pages 2217 - 2228, XP002716011 | |
| OPPOSITION | - SIERRO, S. et al., "Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti- tumor immunity", Eur. J. Immunol., vol. 41, doi:10.1002/eji.201041235, pages 2217 - 2228, XP002716011 | |
| OPPOSITION | - SIERRO, SOPHIE R. et al., "Combination of 2011 lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity", European journal of immunology, (20110000), vol. 41.8, doi:10.1002/eji.201041235, pages 2217 - 2228, XP055053701 | |
| OPPOSITION | - MKRTICHYAN et al., "Anti-PD-1 synergizes with cyclophosphamide to induce potent anti- tumor vaccine effects through novel mechanisms", European Journal of Immunology, (20110000), vol. 41, doi:10.1002/eji.201141639, pages 2977 - 2986, XP055497998 | |
| OPPOSITION | - MKRTICHYAN et al., "Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms", Immunomodulation, (20110000), vol. 41, pages 2977 - 2986, XP055497998 | |
| OPPOSITION | - BLANK, CHRISTIAN et al., "Blockade of PD-L1 (B7- 2006 H1) augments human tumor-specific T cell responses", Int. J. Cancer, (20060000), vol. 119, doi:10.1002/ijc.21775, pages 317 - 327, XP002557386 | |
| OPPOSITION | - FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", J Gene Med, (20120600), vol. 14, pages 428 - 439, XP002716014 | |
| OPPOSITION | - FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", Journal of Gene Medicine, (20120000), vol. 14, doi:10.1002/jgm.2605, pages 428 - 439, XP002719717 | |
| OPPOSITION | - FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", The Journal of Gene Medicine, (20120000), vol. 14, pages 428 - 439, XP002716014 | |
| OPPOSITION | - FOTIN-MLECZEK, MARIOLA et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", The journal of gene medicine, (20120000), vol. 14.6, pages 428 - 439, XP002716014 | |
| OPPOSITION | - FOTIN-MLECZEK, M. et al., "Highly potent mRNA-based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", J Gene Med, (20120000), vol. 14, doi:10.1002/jgm.2605, pages 428 - 439, XP002719717 | |
| OPPOSITION | - FOTIN-MLECZEK, M. et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", Journal of Gene Medicine, (20120000), vol. 14, pages 428 - 439, XP002716014 | |
| OPPOSITION | - STRAIN, DANIEL, "Crushing Cancer's Defenses Vaccine approval offers hope while other armies muster", Science News, (20110000), vol. 179.10, doi:10.1002/scin.5591791020, pages 20 - 23, XP055493182 | |
| OPPOSITION | - MONIE, ARCHANA et al., "Modification of Dendritic Cells to Enhance Cancer Vaccine Potency.", Targeted Cancer Immune Therapy, New York, NY, (20090000), doi:10.1007/978-1-4419-0170-5, pages 133 - 157, XP055493069 | |
| OPPOSITION | - MONIE et al., "Modification of dendritic cells to enhance cancer vaccine potency", Targeted cancer immune therapy, XP055493069 | |
| OPPOSITION | - Pascolo Steve, "Vaccination with messenger RNA (mRNA)", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY., SPRINGER VERLAG, BERLIN, DE, BERLIN, DE, (20080101), no. 183, doi:10.1007/978-3-540-72167-3_11, ISSN 0171-2004, pages 221 - 235, XP001538300 | |
| OPPOSITION | - HOBO et al., "Improving dendritic cell vaccine 2012 ( online ) immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation", Cancer Immunol. Immunother., (20130000), vol. 62, doi:10.1007/s00262-012-1334-1, pages 285 - 297, XP055129027 | |
| OPPOSITION | - HOBO, W. et al., "Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation", Cancer Immunol Immunother, (20130000), vol. 62, doi:10.1007/s00262-012-1334-1, pages 285 - 297, XP055129027 | |
| OPPOSITION | - Sonja Kleffel, Christian Posch, Steven r. Barthel, Hansgeorg Mueller, Christoph Schlapbach, Emmanuella Guenova, Christopher p. Elco, Nayoung Lee, Vikram r. Juneja, Qian Zhan, Christine g. Lian, Rahel Thomi, Wolfram Hoetzenecker, Antonio Cozzio, Reinhard Dummer, Martin c. Mihm, Keith t. Flaherty, Markus h. Frank, George f. Murphy, Arlene h. Sharpe, Thomas s. Kupper, Tobias Schatton, "Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth", Cell, Elsevier, Amsterdam NL, Amsterdam NL , (20150901), vol. 162, no. 6, doi:10.1016/j.cell.2015.08.052, ISSN 0092-8674, pages 1242 - 1256, XP055594329 | |
| OPPOSITION | - KREITER et al., "Tumor vaccination using messenger RNA: prospects of a future therapy", Current Opinion in Immunology, (20110000), vol. 23, pages 399 - 406, XP055018902 | |
| OPPOSITION | - TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Current Opinion in Immunology, (20120000), vol. 24, doi:10.1016/j.coi.2011.12.009, pages 207 - 212, XP002714810 | |
| OPPOSITION | - TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Current Opinion in Immunology, (20120000), vol. 24, pages 207 - 212, XP002714810 | |
| OPPOSITION | - TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Curr Opin Immunol., (20120109), vol. 24, no. 2, pages 207 - 212, XP002714810 | |
| OPPOSITION | - TOPALIAN, S. et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Current Opinion in Immunology, (20120000), vol. 24, pages 207 - 212, XP002714810 | |
| OPPOSITION | - WEIDE et al., "Plasmid DNA- and messenger RNA-based anti-cancer vaccination", Immunology Letters, (20080000), vol. 115, pages 33 - 42, XP022400684 | |
| OPPOSITION | - BUTTE, M. et al., "Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses", Immunity, (20070700), vol. 27, pages 111 - 122, XP055099322 | |
| OPPOSITION | - Jeffrey B. Ulmer; Peter W. Mason; Andrew Geall; Christian W. Mandl;, "RNA-based vaccines", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20120418), vol. 30, no. 30, doi:10.1016/j.vaccine.2012.04.060, ISSN 0264-410X, pages 4414 - 4418, XP028520925 | |
| OPPOSITION | - ULMER et al., "RNA-based vaccines", Vaccine, (20120000), vol. 30, pages 4414 - 4418, XP028520925 | |
| OPPOSITION | - ULMER et al., "RNA-based vaccines", Vaccine, (20120428), vol. 30, no. 30, pages 4414 - 4418, XP028520925 | |
| OPPOSITION | - OMORI, RISA et al., "Effects of interferon-a- 2012 transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.", Cancer Gene Therapy, (20120000), vol. 19.9, doi:10.1038/cgt.2012.42, pages 637 - 643, XP055299990 | |
| OPPOSITION | - DAI, B. et al., "PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell -Directed Lentiviral Vaccines", Molecular Therapy, (20120000), vol. 20, doi:10.1038/mt.2012.98, pages 1800 - 1809, XP002716012 | |
| OPPOSITION | - DAI, B. et al., "PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines", Molecular Therapy, (20120900), vol. 20, no. 9, pages 1800 - 1809, XP002716012 | |
| OPPOSITION | - DAI, BINGBING et al., "PD-1/PD-L1 blockade can 2012 enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell -directed lentiviral vaccines.", Molecular Therapy 20.9, (20120000), vol. 20.9, doi:10.1038/mt.2012.98, pages 1800 - 1809, XP002716012 | |
| OPPOSITION | - DAI et al., "PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell -Directed Lentiviral Vaccines", Molecular Therapy, (20120000), vol. 20, doi:10.1038/mt.2012.98, pages 1800 - 1809, XP002716012 | |
| OPPOSITION | - DAI et al., "PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines", Molecular Therapy, (20120000), vol. 20, no. 9, pages 1800 - 1809, XP002716012 | |
| OPPOSITION | - BARBER, DANIEL L. et al., "Restoring function in 2006 exhausted CD 8 T cells during chronic viral infection", Nature, (20060000), vol. 439, doi:10.1038/nature04444, pages 682 - 687, XP055198624 | |
| OPPOSITION | - GILBOA, ELI, "The promise of cancer vaccines", 2004 Nature Reviews Cancer, (20040000), vol. 4.5, pages 401 - 411, XP055680735 | |
| OPPOSITION | - PARDOLL, DREW M., "The blockade of immune 2012 checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20121204), doi:10.1038/nrc3239, pages 252 - 264, XP055339916 | |
| OPPOSITION | - PARDOLL et al., "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120322), vol. 12, pages 252 - 264, XP055415943 | |
| OPPOSITION | - PARDOLL, "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120000), vol. 12, doi:10.1038/nrc3239, pages 252 - 264, XP055415943 | |
| OPPOSITION | - YAO, SHENG et al., "Advances in targeting cell surface signalling molecules for immune modulation", Nature Reviews Drug Discovery, (20130201), vol. 12.2, pages 130 - 146, XP055157248 | |
| OPPOSITION | - WEBER et al., "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade", Seminars in Oncology, (20101000), vol. 37, no. 5, pages 430 - 439, XP009177527 | |
| OPPOSITION | - WEBER, "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade", Seminars in Oncology, (20100000), vol. 37, no. 5, pages 430 - 439, XP009177527 | |
| OPPOSITION | - WEBER, JEFFREY, "Immune checkpoint proteins: a 2010 new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade", Seminars in oncology, (20100000), vol. 37. 5, doi:10.1053/j.seminoncol.2010.09.005, pages 430 - 439, XP009177527 | |
| OPPOSITION | - RIBAS, "Tumor immunotherapy directed at PD-1", NEJM, (20120000), vol. 366, no. 26, pages 2517 - 2519, XP008178734 | |
| OPPOSITION | - BRAHMER et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", NEJM, (20120000), vol. 366, no. 26, pages 2455 - 2465, XP002685330 | |
| OPPOSITION | - BRAHMER et al., "Safety and Activity of Anti-PD-Ll Antibody in Patients with Advanced Cancer", New England Journal of Medicine, (20120000), vol. 366, doi:10.1056/NEJMoa1200694, pages 2455 - 2465, XP055668316 | |
| OPPOSITION | - CURRAN et al., "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", PNAS, (20100000), vol. 107, no. 9, pages 4275 - 4280, XP055067204 | |
| OPPOSITION | - CURRAN et al., "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", Proc Natl Acad Sci USA., (20100216), vol. 107, no. 9, pages 4275 - 4278, XP055067204 | |
| OPPOSITION | - HA et al., "Enhancing therapeutic vaccination by 2008 blocking PD-1-mediated inhibitory signals during chronic infection", JEM, (20080000), vol. 205, doi:10.1084/jem.20071949, pages 543 - 555, XP007910673 | |
| OPPOSITION | - HA et al., "Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection", J Exp Med., (20080317), vol. 205, no. 3, pages 543 - 555, XP007910673 | |
| OPPOSITION | - HA et al., "Enhancing therapeutic vaccination by blocking PD-1 � mediated inhibitory signals during chronic infection", JEM, (20080000), vol. 205, no. 3, pages 543 - 555, XP007910673 | |
| OPPOSITION | - HA, S-J. et al., "Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection", JEM, (20080317), vol. 205, pages 543 - 555, XP007910673 | |
| OPPOSITION | - FLEETON et al., "Self-Replicative RNA Vaccines Elicit Protection against Influenza A Virus", Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus, Journal of Infectious Diseases, (20010000), vol. 183, doi:10.1086/319857, pages 1395 - 1398, XP002224503 | |
| OPPOSITION | - WONG, RAYMOND M. et al., "Programmed death-1 2007 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs", International immunology, (20070000), vol. 19.10, doi:10.1093/intimm/dxm091, pages 1223 - 1234, XP009105472 | |
| OPPOSITION | - FOTIN-MLECZEK M et al., "Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity", J Immunother, (20110000), vol. 34, pages 1 - 15, XP008144564 | |
| OPPOSITION | - SONG et al., "Enhancement of Vaccine-induced Primary and Memory CD 8+ T- cell Responses by Soluble PD-1", J. Immunother, (20110000), vol. 34, pages 297 - 306, XP055498003 | |
| OPPOSITION | - SONG et al., "Enhancement of Vaccine-induced Primary and Memory CD 8+ T- cell Responses by Soluble PD-1", Journal of Immunotherapy, (20110000), vol. 34, doi:10.1097/CJI.0b013e318210ed0e, pages 297 - 306, XP009515238 | |
| OPPOSITION | - POSTOW et al., "Beyond Cancer Vaccines : A Reason for Future Optimism With Immunomodulatory Therapy", NIH Public Access Author Manuscript, (20110000), vol. 17, no. 5, pages 1 - 13, XP055510153 | |
| OPPOSITION | - POSTOW et al., "Beyond Cancer Vaccines : A Reason for Future Optimism With Immunomodulatory Therapy", NIH Public Access Author Manuscript, (20110900), vol. 17, no. 5, pages 1 - 13, XP055510153 | |
| OPPOSITION | - DURAISWAMY et al., "Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors", Cancer Res., (20130430), vol. 73, no. 12, pages 3591 - 3603, XP055218335 | |
| OPPOSITION | - LI, BETTY et al., "Anti-programmed death-1 2009 synergizes with granulocyte macrophage colony- stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors", Clinical Cancer Research, (20090515), pages 1623 - 1634, XP055166457 | |
| OPPOSITION | - LI et al., "Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors", Clin Cancer Res, (20090000), vol. 15, no. 5, pages 1623 - 1634, XP055166457 | |
| OPPOSITION | - MELERO, IGNACIO et al., "Palettes of vaccines and 2009 immunostimulatory monoclonal antibodies for combination", Clinical Cancer Research, (20090000), vol. 15.5, doi:10.1158/1078-0432.CCR-08-2931, pages 1507 - 1509, XP055493136 | |
| OPPOSITION | - BRAHMER et al., "Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer", Cancer Immunol Res., (20130722), vol. 1, no. 2, pages 85 - 91, XP055198615 | |
| OPPOSITION | - Guido Vanham;Ellen Van Gulck, "Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, GB, (20120907), vol. 9, no. 1, doi:10.1186/1742-4690-9-72, ISSN 1742-4690, page 72, XP021107722 | |
| OPPOSITION | - VANHAM et al., "Can immunotherapy be useful as a ''functional cure'' for infection with Human Immunodeficiency Virus-1?", Retrovirology, (20120000), vol. 9, doi:10.1186/1742-4690-9-72, page 72, XP021107722 | |
| OPPOSITION | - VANHAM et al., "Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?", Retrovirology, (20120000), vol. 9, no. 72, pages 1 - 21, XP021107722 | |
| OPPOSITION | - Pascolo, "DNA Vaccines: Methods and Protocols", Methods in Molecular Medicine, (20060000), vol. 127, no. Second Edition, pages 23 - 40, XP009117840 | |
| OPPOSITION | - PASCOLO, "Vaccination With Messenger RNA", Methods in Molecular Medicine, (20060000), vol. 127, pages 23 - 40, XP009117840 | |
| OPPOSITION | - PILON-THOMAS et al., "Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma", J Immunol, (20100301), vol. 184, pages 3442 - 3449, XP002767914 | |
| OPPOSITION | - ZHOU et al., "Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization", Journal of Immunology, (20100000), vol. 185, doi:10.4049/jimmunol.1001821, pages 5082 - 5092, XP055497999 | |
| OPPOSITION | - ZHOU et al., "Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization", The Journal of Immunology, (20100000), vol. 185, pages 5082 - 5092, XP055497999 | |
| OPPOSITION | - ROSSI et al., "Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity", J Immunol, (20050801), vol. 175, pages 1373 - 1381, XP055510144 | |
| OPPOSITION | - ZITVOGEL et al., "Targeting PD-1/PD-L1 interactions for cancer immunotherapy", Oncolmmunology, (20120000), vol. 1, no. 8, pages 1223 - 1225, XP002716013 | |
| OPPOSITION | - ZITVOGEL, LAURENCE et al., "Targeting PD-1/PD-L1 interactions for cancer immunotherapy", Oncolmmunology, (20120000), vol. 1.8, doi:10.4161/onci.21335, pages 1223 - 1225, XP002716013 | |
| OPPOSITION | - ZITVOGEL, L. et al., "Targeting PD-1/PD-L1 interactions for cancer immunotherapy", Oncoimmunology, (20121100), vol. 1, no. 8, pages 1223 - 1225, XP002716013 | |
| OPPOSITION | - SCHLAKE et al., "Developing mRNA-vaccine technologies", RNA Biology, (20120000), vol. 11, doi:10.4161/rna.22269, pages 1319 - 1330, XP055561756 | |
| OPPOSITION | - SCHLAKE et al., "Tumor vaccination using messenger RNA: prospects of a future therapy", RNA Biology, (20120000), vol. 9, no. 11, pages 1319 - 1330, XP002743467 | |
| OPPOSITION | - ICLOZAN, CRISTINA et al., "Recent advances in immunotherapy of lung cancer", Journal of Lung Cancer, (20120000), vol. 11.1, doi:10.6058/jlc.2012.11.1.1, pages 1 - 11, XP055493027 | |
| SEARCH | - SIERRO SOPHIE R ET AL, "Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.", EUROPEAN JOURNAL OF IMMUNOLOGY AUG 2011, (201108), vol. 41, no. 8, ISSN 1521-4141, pages 2217 - 2228, XP002716011 [X] 1-4,17-21 * abstract * * page 2218, column 2, paragraph 1 * * page 2222, column 2, paragraph l - page 2223, column 2, paragraph 2 * [Y] 5-9,11-13,15,16 | |
| SEARCH | - FOTIN-MLECZEK MARIOLA ET AL, "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", JOURNAL OF GENE MEDICINE, (201206), vol. 14, no. 6, pages 428 - 439, XP002716014 [Y] 11-13,15-17 * the whole document * | |
| SEARCH | - DAI BINGBING ET AL, "PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY SEP 2012, (201209), vol. 20, no. 9, ISSN 1525-0024, pages 1800 - 1809, XP002716012 [XD] 1-4,17-21 * the whole document * [Y] 5-9,11-13,15,16 | |
| SEARCH | - ZITVOGEL LAURENCE ET AL, "Targeting PD-1/PD-L1 interactions for cancer immunotherapy", ONCOIMMUNOLOGY, (201211), vol. 1, no. 8, pages 1223 - 1225, XP002716013 [Y] 5,6 * page 1224, column 2, paragraph 3 * | |
